Published in Clinical Trials Week, December 3rd, 2007
"I am delighted that we are now dosing patients in our Phase 2 study to evaluate the efficacy of ARRY-797 in the management of postoperative dental pain," said John Yates, MB ChB, MD, Chief Medical Officer, Array BioPharma. "We believe we are likely to see significant efficacy in acute pain based upon ARRY-797's pharmacodynamic activities to date. This model has been a good predictor of acute analgesic effects of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.